Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878334 | 0.93 | ALDH1A1 (0.67) | ALDH1A1USP2HTTSMN1; SMN2KMT2A | |
| SCHEMBL4880697 | 0.79 | HTT (0.61) | ALDH1A1USP2HTTSMN1; SMN2KMT2A | |
| SCHEMBL4878644 | 0.78 | ENPP2 (0.66) | ALDH1A1USP2HTTSMN1; SMN2ENPP2 | |
| SCHEMBL4881075 | 0.77 | HSD17B10 (0.65) | ALDH1A1USP2KMT2ACYP3A4CYP2D6 | |
| SCHEMBL31157807 | 0.64 | ALDH1A1 (0.71) | ALDH1A1HTTKMT2ACYP3A4CYP2D6 | |
| SCHEMBL30957223 | 0.63 | HTT (0.72) | ALDH1A1HTTKMT2ACYP3A4CYP2D6 | |
| SCHEMBL12044572 | 0.62 | PTPN1 (0.70) | SMN1; SMN2NPC1 | |
| SCHEMBL11832814 | 0.61 | PTPN1 (0.63) | ALDH1A1SMN1; SMN2KMT2ALMNANPC1 | |
| SCHEMBL6416083 | 0.61 | NPC1 (0.60) | HTTSMN1; SMN2KMT2ALMNACYP2C9 | |
| SCHEMBL14281213 | 0.61 | MEN1 (0.60) | SMN1; SMN2KMT2ALMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1698335-A1 | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DISEASE IN WHICH MITOCHONDRIAL BENZODIAZEPINE RECEPTOR PARTICIPATES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249154-A1 | Preventive and/or Therapeutic Agent For Disease In Which Mitochondrial Benzodiazephine Receptor Participates | MTNR1A, GSR, NLN | ALDH1A1 1371/4885USP2 4686/4885HTT 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.